Skip to content
Wockhardt
  • Home
  • About Us
    • Chairman’s Profile
    • Board Of Directors
    • Team Wockhardt
    • Corporate Milestones
    • Research & Development
      • R&D at Wockhardt
      • New Drug Discovery
        • Pipeline / Projects
        • News & Events
        • Publications
          • ZAYNICH®
          • WCK 4873
          • WCK 4282
          • WCK 6777
      • Biologicals
        • News & Events
        • Pipeline / Projects
        • Publications
      • R&D Contact
    • Our Manufacturing Units
      • Shendra, India
      • Biotech Park, India
      • Daman, India
      • Ankleshwar, India
    • Global Footprint
      • India
      • UK & Europe
      • Emerging Markets
    • Products
      • India Branded Business
      • API
      • Russia – CIS
      • UK
      • Irish Market
      • Emerging Markets
      • Quality Generics
    • Quality Policy
  • Investors
    • From Chairman’s Office
      • AGM Speech
      • Letter to Shareowners
    • Financials
      • Annual Report
      • Quarterly Results
      • Financial Press Releases
      • Related Party Transactions
    • Subsidiary Financials
    • Annual Return
    • Corporate Governance
      • Policies & Codes
      • Committee’s of the Board
      • Familiarisation programs
      • Shareholding Pattern
      • Secretarial Compliance Report
      • Authorised KMP
      • Corporate Actions
      • Memorandum of Association and Article of Association
      • ESOP Scheme
      • Disclosures under Regulation 46 of SEBI LODR Regulations
    • Announcements / Disclosures
    • Shareholders Meeting / Postal ballot
      • AGM Notice
      • Proceedings
      • Voting Results
      • Transcript of the AGM
    • IEPF
      • Unclaimed Dividend
      • Nodal Officer
    • Analyst/ Investors
      • Presentation
      • Audio / Video Recording
      • Transcript
    • Shareowner Services
      • FAQ
      • Green Initiative
      • Investor Contact
      • Other Notices
      • Credit Rating
  • careers
    • Introduction
    • Life@Wockhardt
    • L&D Initiatives
    • Voice of Wockhardians
    • Career@Wockhardt
  • Media
    • Press Releases
    • Wockhardt in Media
  • ESG
  • Contact us

Home / About Us / Research and Development / Biologicals / Publications

Publications

    • download image

      December 2020 Technical Evaluation Summary By National Pharmaceutical Regulatory Division Ministry Of Health Malaysia – Glaritus Biosimilar approval

    • download image

      June 2020 Six Months Comparative Evaluation of Efficacy and Safety of Wockhardt’s Biosimilar Insulin Glargine (Glaritus®) with Reference Insulin Glargine (Lantus®) in Type 2 Diabetes Mellitus in India: Results of Interim Analysis

    • download image

      JFebruary 2019 Assessment of Safety and Effectiveness of Glaritus® (Wockhardt’s Insulin Glargine) in a Prospective, Multi-Centric Post Marketing Observational Study in Nepalese Having Type 2 Diabetes Mellitus

    • download image

      February 2018 Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus®) and Lantus® in healthy subjects: a double-blind, randomized clamp study

    • download image

      August 2018 Immunogenicity, Safety and Efficacy Comparison of Wockhardt’s Biosimilar Insulin Glargine—Glaritus® with Reference Product— Lantus®: Study Protocol & Early Data Trends

    • download image

      April 2017 Evaluation of Safety and Efficacy of Glaritus® versus Lantus® in Combination with Insulin Lispro among Adults with Type 1 Diabetes Mellitus-Phase IV Study

Quick Links

  • Home
  • About Us
  • Investors
  • Careers
  • Media
  • ESG
  • Contact Us
  • Pharmacovigilance – Adverse Event Reporting
  • Privacy Policy
  • Archival Policy
  • Terms and Conditions

Get in Touch

D-4 MIDC, Chikalthana
Chhatrapati Sambhajinagar, 431006, India
91-22-2653 4444
contactus@wockhardt.com
Corporate Identity Number: L24230MH1999PLC120720

Wock Stock

wpChatIcon